検索
Beigene Ltd
ONCウォッチリストに追加
315.970USD
-6.110-1.90%
終値 07-31 16:00（ET）15分遅れの株価
32.31B時価総額
67.69直近12ヶ月PER
詳細情報 Beigene Ltd 企業名
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltdの企業情報
企業コードONC
会社名BeOne Medicines AG
上場日Mar 02, 2016
最高経営責任者「CEO」Oyler (John Victor)
従業員数11000
証券種類Depository Receipt
決算期末Mar 02
本社所在地c/o BeOne Medicines I GmbH
都市BASEL
証券取引所NASDAQ OMX - NASDAQ BASIC
国Switzerland
郵便番号4051
電話番号41616851900
ウェブサイトhttps://beonemedicines.com/
企業コードONC
上場日Mar 02, 2016
最高経営責任者「CEO」Oyler (John Victor)
Beigene Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
11.61K
-41.00%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
よくある質問
Beigene Ltdの上位5名の株主は誰ですか？
Beigene Ltdの上位5名の株主は以下のとおりです。Dr. Xiaobin Wu, Ph.D.
Beigene Ltd（ONC）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Beigene Ltdの株式を保有している機関は602社あり、保有株式の総市場価値は約40.42Mで、全体の36.84%を占めています。2025Q4と比較して、機関の持ち株は1961186.00増加しています。
Beigene Ltdの最大の収益源は何ですか？
2026Q1において、Product部門がBeigene Ltdにとって最大の収益を生み出しており、その金額は1.37Bで、全収益の97.35%を占めています。